Points clés
- 1Graft loss is irreversible by the previous product — any manufacturer switch had to be supervised with trough-level monitoring.
- 2The transplant centre's documented process made the switch safe: baseline troughs, recheck at day 7 and 14, dose adjusted once, stable thereafter.
- 3Staying on a consistent manufacturer matters more than which approved product wins on price for narrow-therapeutic-index drugs.
- 4Extra monitoring during the switch cost a fraction of what he saved — and it was exactly what made the saving safe.
Aperçu du cas
- Profil du patient
- Composite profile — 39-year-old, two years post kidney transplant
- Pays
- Poland
- Affection
- Kidney transplant recipient
- Médicament
- Tacrolimus, mycophenolate mofetil, prednisolone
Coût occidental
~$8,900 per year
Alternative de référence
~$1,020 per year reference
Impact
~$7,880 per year
Sur cette page
1Why transplant medicine is different
Immunosuppression after a transplant is lifelong and unforgiving. Too little drug risks rejection and loss of the graft; too much increases infection and malignancy risk. The therapeutic window is narrow.
Tacrolimus in particular is a narrow-therapeutic-index drug, dosed to a measured blood trough level rather than to a fixed milligram amount. That single fact governs everything about how a switch must be handled.
2The situation
Two years post-transplant with stable graft function, the patient changed jobs and lost supplementary coverage that had absorbed most of his medication cost. He faced the full cost of three medicines indefinitely.
He contacted his transplant coordinator before making any change — which is the single most important action in this entire case.
3The supervised switch protocol
The transplant centre had a defined process for manufacturer changes, because generic substitution at pharmacy level is a recognised issue in transplant care.
- 1Baseline tacrolimus trough levels documented across three measurements.
- 2Baseline creatinine and eGFR recorded.
- 3A single named generic manufacturer selected, with a commitment to stay on that product rather than accept pharmacy-level switching between suppliers.
- 4Switch made with trough level rechecked at 7 and 14 days.
- 5Dose adjusted to bring the trough back into the target range.
- 6Creatinine monitored monthly for three months.
- 7The specific product recorded in his notes so future dispensing stayed consistent.
| Medicine | Before | After | Reduction |
|---|---|---|---|
| Tacrolimus 1 mg | ~$5,800 | ~$640 | 89% |
| Mycophenolate mofetil 500 mg | ~$2,400 | ~$290 | 88% |
| Prednisolone 5 mg | ~$260 | ~$34 | 87% |
| Additional trough monitoring | $440 | $56 | 87% |
| Annual total | ~$8,900 | ~$1,020 | 89% |
4Consistency matters more than price
The most important instruction he received was not about which product to use but about staying on it. Repeated switching between different generic manufacturers is the specific risk in narrow-therapeutic-index therapy, because each switch can shift trough levels.
He asked his pharmacy to record a note preventing automatic substitution between suppliers, and to contact the transplant team if his usual product became unavailable.
5Outcome
Trough levels required one dose adjustment at day 14 and were stable thereafter. Creatinine and eGFR remained at baseline through twelve months, with no rejection episode.
He describes the extra monitoring as the part that made the switch feel safe rather than reckless — and it cost a fraction of what he saved.
6About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Statistics alone cannot carry the weight of a decision about medicine. A line like 'the same course is 340 times cheaper' means nothing until you can see what it did to one household's bills, monitoring schedule and peace of mind.
The only reason we show any switch is to illustrate a pattern. Your own move must be planned with your prescriber.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Ce que montre le jeu de données Jivan
- 29.2×
- écart moyen de prix Transplant
- 75%
- des ancres dépassent 10×
- 45×
- plus grand écart documenté
Across our Transplant anchors, 8 referenced molecules average a 29.2× price gap, 75% of them are at least 10× cheaper in India, and the widest documented comparison is Tacrolimus at 45×. Transplant anchors show narrower-than-average ratio spreads between different generic manufacturers of the same molecule — consistent with the clinical demand for formulation consistency.
Calculé en direct à partir de 8 anchors
Questions fréquentes
Yes, generic immunosuppressants are widely used, but the switch must be supervised with trough-level monitoring, and patients should then remain on a consistent manufacturer rather than switching repeatedly.
For narrow-therapeutic-index drugs, small differences in absorption between products can shift blood levels. Each switch introduces variability, so consistency reduces risk.
Trough levels typically at around 7 and 14 days, dose adjustment as required, and renal function monitoring for several months, following the transplant centre's own protocol.
Sources et lectures complémentaires
Chaque fait ci-dessus est traçable vers une source primaire publique. Nous citons les régulateurs et les organismes de santé publique, pas les vendeurs commerciaux.
- 1Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)U.S. Food & Drug Administration
- 2Generic and Hybrid MedicinesEuropean Medicines Agency
- 3MedlinePlus Drug InformationU.S. National Library of Medicine
- 4WHO Model List of Essential MedicinesWorld Health Organization
Comment cet article a été rédigé
Rédigé et recherché
Pricing Research Editor, Jivan Editorial TeamRelu éditorialement
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Avertissement médical important
Consultez toujours un médecin avant de changer de médicament, de dose ou de marque. Jivan fournit des informations éducatives et tarifaires et ne remplace ni un diagnostic ni les soins d'urgence.